UB Paderborn / Katalog / Suche / in CDI

Electron Ghost Imaging

Physical review letters, 2018-09, Vol.121 (11), p.114801-114801, Article 114801

2018

Volltextzugriff (PDF)

Combination of Trastuzumab and Tanespimycin (17-AAG, KOS-953) Is Safe and Active in Trastuzumab-Refractory HER-2–Overexpressing Breast Cancer: A Phase I Dose-Escalation Study

Journal of clinical oncology, 2007-12, Vol.25 (34), p.5410-5417

2007

Volltextzugriff (PDF)

Interactive effects of dehydroepiandrosterone and testosterone on cortical thickness during early brain development

The Journal of neuroscience, 2013-06, Vol.33 (26), p.10840-10848

2013

Volltextzugriff (PDF)

Virtual-diagnostic-based time stamping for ultrafast electron diffraction

Physical review. Accelerators and beams, 2023-05, Vol.26 (5), p.052801, Article 052801

2023

Volltextzugriff (PDF)

Relativistic ultrafast electron diffraction at high repetition rates

Structural dynamics (Melville, N.Y.), 2023-11, Vol.10 (6), p.064302-064302

2023

Volltextzugriff (PDF)

Mapping photocathode quantum efficiency with ghost imaging

Physical review. Accelerators and beams, 2020-02, Vol.23 (2), p.022803, Article 022803

2020

Volltextzugriff (PDF)

Dose-Finding and Pharmacokinetic Study of Cisplatin, Gemcitabine, and SU5416 in Patients With Solid Tumors

Journal of clinical oncology, 2002-03, Vol.20 (6), p.1657-1667

Kuenen, B. C.

2002

Volltextzugriff (PDF)

Spatial location influences vocal interactions in bullfrog choruses

The Journal of the Acoustical Society of America, 2010-04, Vol.127 (4), p.2664-2677

2010

Volltextzugriff (PDF)

Negotiation of territorial boundaries in a songbird

Behavioral ecology, 2014-11, Vol.25 (6), p.1436-1450

2014

Volltextzugriff (PDF)

Pediatric phase I trial and pharmacokinetic study of the platelet-derived growth factor (PDGF) receptor pathway inhibitor SU101

Cancer chemotherapy and pharmacology, 2004-06, Vol.53 (6), p.482-488

2004

Volltextzugriff (PDF)

Seeking American Society of Clinical Oncology‐Quality Oncology Practice Initiative (ASCO‐QOPI) certification in a northern New England rural health system and cancer care network

Learning health systems, 2024-07, Vol.8 (3), p.e10415-n/a

2024

Volltextzugriff (PDF)

Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer

American journal of clinical oncology, 2006-04, Vol.29 (2), p.109-115

2006

Volltextzugriff (PDF)

Phase I dose escalation study of KOS-1584, a novel epothilone, in patients with advanced solid tumors

Cancer chemotherapy and pharmacology, 2012-02, Vol.69 (2), p.523-531

2012

Volltextzugriff (PDF)

A phase 1 study of KOS-862 (Epothilone D) co-administered with carboplatin (Paraplatin®) in patients with advanced solid tumors

Investigational new drugs, 2012-08, Vol.30 (4), p.1676-1683

2012

Volltextzugriff (PDF)

Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in Patients with solid tumors

Journal of clinical oncology, 2002-03, Vol.20 (6), p.1657-1667

2002

Volltextzugriff (PDF)

Ultrafast photo-induced melting of the trimer superstructure in TaTe2

2021 Conference on Lasers and Electro-Optics (CLEO), 2021, p.1-2

2021

Volltextzugriff (PDF)

Clinical trial of the novel structure proteasome inhibitor NPI-0052 in patients with relapsed and relapsed/refractory multiple myeloma (r/r MM)

Journal of clinical oncology, 2009-05, Vol.27 (15_suppl), p.8505-8505

2009

Volltextzugriff (PDF)

Phase 1 Clinical Trial of the Novel Structure Proteasome Inhibitor NPI-0052 in Patients with Relapsed and Relapsed/Refractory Multiple Myeloma (MM)

Blood, 2009-11, Vol.114 (22), p.431-431

2009

Volltextzugriff (PDF)

Tanespimycin (T) + bortezomib (BZ) in multiple myeloma (MM): Pharmacology, safety and activity in relapsed/refractory (rel/ref) patients (Pts)

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.3532-3532

2007

Volltextzugriff (PDF)

Phase 1 Clinical Trial of a Novel Proteasome Inhibitor (NPI-0052) in Patients with Lymphomas and Solid Tumors

Blood, 2007-11, Vol.110 (11), p.4504-4504

2007

Volltextzugriff (PDF)

Phase 1 trial of KOS-862 (epothilone D) in combination with carboplatin (C) in patients with solid tumors

Journal of clinical oncology, 2005-06, Vol.23 (16_suppl), p.2049-2049

2005

Volltextzugriff (PDF)

Dose escalating trial of 17-AAG with bortezomib (BZ) in patients with relapsed refractory multiple myeloma (MM)

Journal of clinical oncology, 2005-06, Vol.23 (16_suppl), p.6682-6682

2005

Volltextzugriff (PDF)

Phase 1 trial of 17-AAG in patients with relapsed and refractory multiple myeloma (MM)

Journal of clinical oncology, 2005-06, Vol.23 (16_suppl), p.3056-3056

2005

Volltextzugriff (PDF)

Phase 1 and pharmacokinetic (PK) study of weekly KOS-862 (Epothilone D) combined with gemcitabine (GEM) in patients (Pts) with advanced solid tumors

Journal of clinical oncology, 2005-06, Vol.23 (16_suppl), p.2041-2041

2005

Volltextzugriff (PDF)

Safety and Activity of KOS-953 in Patients with Relapsed Refractory Multiple Myeloma (MM): Interim Results of a Phase 1 Trial

Blood, 2005-11, Vol.106 (11), p.361-361

2005

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Electron Ghost Imaging

Combination of Trastuzumab and Tanespimycin (17-AAG, KOS-953) Is Safe and Active in Trastuzumab-Refractory HER-2–Overexpressing Breast Cancer: A Phase I Dose-Escalation Study

Interactive effects of dehydroepiandrosterone and testosterone on cortical thickness during early brain development

Virtual-diagnostic-based time stamping for ultrafast electron diffraction

Relativistic ultrafast electron diffraction at high repetition rates

Mapping photocathode quantum efficiency with ghost imaging

Dose-Finding and Pharmacokinetic Study of Cisplatin, Gemcitabine, and SU5416 in Patients With Solid Tumors

Spatial location influences vocal interactions in bullfrog choruses

Negotiation of territorial boundaries in a songbird

Pediatric phase I trial and pharmacokinetic study of the platelet-derived growth factor (PDGF) receptor pathway inhibitor SU101

Seeking American Society of Clinical Oncology‐Quality Oncology Practice Initiative (ASCO‐QOPI) certification in a northern New England rural health system and cancer care network

Phase I/pilot study of SU5416 (semaxinib) in combination with irinotecan/bolus 5-FU/LV (IFL) in patients with metastatic colorectal cancer

Phase I dose escalation study of KOS-1584, a novel epothilone, in patients with advanced solid tumors

A phase 1 study of KOS-862 (Epothilone D) co-administered with carboplatin (Paraplatin®) in patients with advanced solid tumors

Dose-finding and pharmacokinetic study of cisplatin, gemcitabine, and SU5416 in Patients with solid tumors

Ultrafast photo-induced melting of the trimer superstructure in TaTe2

Clinical trial of the novel structure proteasome inhibitor NPI-0052 in patients with relapsed and relapsed/refractory multiple myeloma (r/r MM)

Phase 1 Clinical Trial of the Novel Structure Proteasome Inhibitor NPI-0052 in Patients with Relapsed and Relapsed/Refractory Multiple Myeloma (MM)

Tanespimycin (T) + bortezomib (BZ) in multiple myeloma (MM): Pharmacology, safety and activity in relapsed/refractory (rel/ref) patients (Pts)

Phase 1 Clinical Trial of a Novel Proteasome Inhibitor (NPI-0052) in Patients with Lymphomas and Solid Tumors

Phase 1 trial of KOS-862 (epothilone D) in combination with carboplatin (C) in patients with solid tumors

Dose escalating trial of 17-AAG with bortezomib (BZ) in patients with relapsed refractory multiple myeloma (MM)

Phase 1 trial of 17-AAG in patients with relapsed and refractory multiple myeloma (MM)

Phase 1 and pharmacokinetic (PK) study of weekly KOS-862 (Epothilone D) combined with gemcitabine (GEM) in patients (Pts) with advanced solid tumors

Safety and Activity of KOS-953 in Patients with Relapsed Refractory Multiple Myeloma (MM): Interim Results of a Phase 1 Trial

Suchergebnisse filtern